ReviewMicroorganisms2022
The Use of Artificial Sputum Media to Enhance Investigation and Subsequent Treatment of Cystic Fibrosis Bacterial Infections.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- Exploring the spatial distribution of biomolecules inBiofilm · 2026Article
- Bridging bench and bedside: translational omics ofEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- A novel cystic fibrosis-mimetic Pseudomonas auxotrophic vaccine is protective in vivo and is associated with IL-17/IgA mucosal Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Volatile organic compound profiling for tracking clinical Pseudomonas aeruginosa isolates.Scientific reports · 2026Article
- Microenvironmental effects of a non-antibiotic therapy for a chronic Polymicrobial infection Alter microbial physiology, competition, and virulence.The ISME journal · 2026Article
- Review
- Proteomic characterization ofVirulence · 2025Article
- Metabolomic profiling reveals unique markers for Pseudomonas aeruginosa LasR deficiency.Scientific reports · 2025Article
- Simulated Media for Mimicking the Human Environment In Vitro.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Review
- Exploring nagZ as a virulence biomarker and treatment target in Enterobacter cloacae.BMC microbiology · 2025Article
- Optimizing synthetic cystic fibrosis sputum media for growth of non-typeable Haemophilus influenzae.Access microbiology · 2025Article
- Article
- Iron content of commercial mucin contributes to compositional stability of a cystic fibrosis airway synthetic microbiota community.bioRxiv : the preprint server for biology · 2024Article
- 'Wild Type'.Microbiology (Reading, England) · 2024Review
- Impact of Growth Conditions on High-Throughput Identification of Repurposing Drugs forAntibiotics (Basel, Switzerland) · 2024Article
- Recreating chronic respiratory infectionsEuropean respiratory review : an official journal of the European Respiratory Society · 2024Review
- Mucus polymer concentration andmBio · 2024Article
- ThemBio · 2024Article
- Article
- How Does Airway Surface Liquid Composition Vary in Different Pulmonary Diseases, and How Can We Use This Knowledge to Model Microbial Infections?Microorganisms · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In cystic fibrosis (CF), mutations in the CF transmembrane conductance regulator protein reduce ionic exchange in the lung, resulting in thicker mucus, which impairs mucociliary function, airway inflammation and infection. The mucosal and nutritional environment of the CF lung is inadequately mimicked by commercially available growth media, as it lacks key components involved in microbial pathogenesis. Defining the nutritional composition of CF sputum has been a long-term goal of in vitro research into CF infections to better elucidate bacterial growth and infection pathways. This narrative review highlights the development of artificial sputum medium, from a viable in vitro method for understanding bacterial mechanisms utilised in CF lung, to uses in the development of antimicrobial treatment regimens and examination of interactions at the epithelial cell surface and interior by the addition of host cell layers. The authors collated publications based on a PubMed search using the key words: "artificial sputum media" and "cystic fibrosis". The earliest iteration of artificial sputum media were developed in 1997. Formulations since then have been based either on published data or chemically derived from extracted sputum. Formulations contain combinations of mucin, extracellular DNA, iron, amino acids, and lipids. A valuable advantage of artificial sputum media is the ability to standardise media composition according to experimental requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.